Results 161 to 170 of about 6,309 (194)

Differentiating the solution structures and stability of transthyretin tetramer complexed with tolcapone and tafamidis using SEC-SWAXS and NMR. [PDF]

J Appl Crystallogr
Shih O, Feng YC, Agrawal S, Liao KF, Yeh YQ, Chang JW, Yu TY, Jeng US.   +7 more
europepmc   +1 more source

Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy. [PDF]

Cardiol Ther
Margolin E, Stern LK, Argiro A, Rosenthal JL, Urey MA, Alexander KM.   +5 more
europepmc   +1 more source

Concurrent light chain and transthyretin cardiac amyloidosis: A case report and review of the literature. [PDF]

Medicine (Baltimore)
Sun H, Zhang N, Liu X, Wang M, Wang L, Li Y.   +5 more
europepmc   +1 more source

Misfolded Fate: A Case Report of Transthyretin Cardiac Amyloidosis in Ghana. [PDF]

Cureus
Dzebu AS.
europepmc   +1 more source

Differential Binding Affinities and Kinetics of Transthyretin Stabilizers. [PDF]

J Cardiovasc Pharmacol
Ji AX, Betz A, Sinha U.
europepmc   +1 more source

Comparing Effects of Tafamidis in Controlling Left Ventricular and Left Atrial Strains in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy. [PDF]

Circ Rep
Eguchi C, Kawano H, Nishizawa RH, Yoshimuta T, Ohno C, Kojima S, Minami T, Sato D, Eguchi M, Okano S, Ikeda S, Ueda M, Maemura K.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Tafamidis

Cardiology in Review, 2020
Transthyretin (TTR) amyloid cardiomyopathy is a life-threatening condition in which amyloid fibrils accumulate in the heart, eventually leading to cardiac symptomatology and death. To date, treatment of this condition has been directed at symptom relief due to a lack of effective treatment options which target the cause of the disease.
James J, Nawarskas, Emily A, Shephard
openaire   +2 more sources

Tafamidis Meglumine (Vyndaqel)

Canadian Journal of Health Technologies, 2022
CADTH recommends that Vyndaqel should be reimbursed by public drug plans for the treatment of transthyretin-mediated amyloidosis (ATTR) if certain conditions are met. Vyndaqel should only be covered to treat adult patients who have a documented diagnosis of cardiomyopathy caused by ATTR.
openaire   +1 more source

Tafamidis for Transthyretin Amyloid Cardiomyopathy

New England Journal of Medicine, 2019
Abstract not ...
Maurer, Mathew S, Sultan, Marla B, Rapezzi, Claudio   +2 more
openaire   +4 more sources